Display options
Cite
Ajluni N, Dar M, Xu J, et al. Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program. J Diabetes Metab. 2016;7(3)doi: 10.4172/2155-6156.1000659.
Ajluni, N., Dar, M., Xu, J., Neidert, A. H., & Oral, E. A. (2016). Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program. Journal of diabetes & metabolism, 7(3), . https://doi.org/10.4172/2155-6156.1000659
Ajluni, Nevin, et al. "Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program." Journal of diabetes & metabolism vol. 7,3 (2016). doi: https://doi.org/10.4172/2155-6156.1000659
Ajluni N, Dar M, Xu J, Neidert AH, Oral EA. Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program. J Diabetes Metab. 2016 Mar;7(3). doi: 10.4172/2155-6156.1000659. Epub 2016 Mar 23. PMID: 27642538; PMCID: PMC5026130.
Copy Download .nbib Format: NLM
Share it on

J Diabetes Metab. 2016 Mar;7(3). doi: 10.4172/2155-6156.1000659. Epub 2016 Mar 23.

Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program.

Journal of diabetes & metabolism

Nevin Ajluni, Moahad Dar, John Xu, Adam H Neidert, Elif A Oral

Affiliations

  1. Brehm Center for Diabetes Research and Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI, USA.
  2. Greenville Veterans Affairs Health Care Center, Division of Endocrinology and Metabolism, Brody School of Medicine, East Carolina University, Greenville, NC, USA.
  3. AstraZeneca, Gaithersburg, MD, USA.

PMID: 27642538 PMCID: PMC5026130 DOI: 10.4172/2155-6156.1000659

Abstract

OBJECTIVE: Patients with lipodystrophy have severe metabolic abnormalities (insulin resistance, diabetes, and hypertriglyceridemia) that may increase morbidity and mortality. Metreleptin is approved by the United States Food and Drug Administration for treatment of generalized forms of lipodystrophy. We aimed to determine the efficacy and safety of metreleptin among patients with partial lipodystrophy using an expanded-access model.

METHODS: Study FHA101 (ClinicalTrials.gov identifier: NCT00677313) was an open-label, expanded-access, long-term clinical effectiveness and safety study in 23 patients with partial lipodystrophy and diabetes and/or hypertriglyceridemia with no prespecified leptin level. Metreleptin was administered subcutaneously at 0.02 mg/kg twice daily (BID) at Week 1, followed by 0.04 mg/kg BID at Week 2. Dose adjustments thereafter were based on patient response (maximum dose of 0.08 mg/kg BID). One-year changes in glycated hemoglobin (HbA1c), fasting plasma glucose, triglycerides, alanine and aspartate aminotransferases, and treatment-emergent adverse events (TEAEs) were evaluated.

RESULTS: HbA1c, fasting plasma glucose, and triglycerides were numerically decreased throughout 1 year, with mean (standard error) changes from baseline of -0.88 (0.62)%, -42.0 (22.4) mg/dL, and -119.8 (84.1) mg/dL, respectively, which were greater among patients with higher baseline abnormalities. Liver enzymes did not worsen, and the most frequently observed TEAEs (≥ 10% incidence) were mild to moderate and included nausea (39.1%), hypoglycemia (26.1%), and urinary tract infections (26.1%)-all reported previously. There were no reports of clinically significant immune-related adverse events or new safety signals.

CONCLUSIONS: Our clinical observations document the large heterogeneity and disease burden of partial lipodystrophy syndromes and suggest that metreleptin treatment benefits may extend to patients with partial lipodystrophy. Additional studies are needed to confirm these preliminary findings.

Keywords: Diabetes; Hypertriglyceridemia; Metreleptin; Partial lipodystrophy

References

  1. J Clin Endocrinol Metab. 2013 Aug;98(8):E1410-3 - PubMed
  2. Diabetes Care. 2013 Aug;36(8):2247-53 - PubMed
  3. Medicine (Baltimore). 2004 Jan;83(1):18-34 - PubMed
  4. Endocr Pract. 2011 Nov-Dec;17(6):922-32 - PubMed
  5. Endocr Pract. 2010 Mar-Apr;16(2):310-23 - PubMed
  6. Clin Endocrinol (Oxf). 2016 Jan;84(1):141-8 - PubMed
  7. Self Nonself. 2010 Oct;1(4):314-322 - PubMed
  8. J Clin Endocrinol Metab. 2015 Nov;100(11):3967-70 - PubMed
  9. Clin Endocrinol (Oxf). 2016 Jul;85(1):137-49 - PubMed
  10. Diabetol Metab Syndr. 2012 Aug 31;4(1):40 - PubMed
  11. Metabolism. 2007 Apr;56(4):508-16 - PubMed
  12. Leuk Lymphoma. 2016;57(1):45-50 - PubMed
  13. J Clin Endocrinol Metab. 2011 Nov;96(11):3313-25 - PubMed
  14. N Engl J Med. 2002 Feb 21;346(8):570-8 - PubMed
  15. J Clin Endocrinol Metab. 2012 Mar;97(3):785-92 - PubMed
  16. Endocr Pract. 2010 Mar-Apr;16(2):324-33 - PubMed
  17. J Clin Endocrinol Metab. 1999 Jan;84(1):170-4 - PubMed
  18. J Clin Endocrinol Metab. 2015 May;100(5):1802-10 - PubMed
  19. J Clin Endocrinol Metab. 2015 Jun;100(6):2231-8 - PubMed
  20. Endocr Pract. 2013 Jan-Feb;19(1):107-16 - PubMed
  21. Diabetologia. 2010 Jan;53(1):27-35 - PubMed

Publication Types

Grant support